A role for activator of G-protein signaling 3 (AGS3) in multiple myeloma

International Journal of Hematology

Volumn 99, Issue 1, 2014, Pages 57-68

  Shao, Shan ^a   Huang, Xianting ^b   Wang, Yuchan ^b   He, Song ^c   Xu, Xiaohong ^c   Zhu, Xinghua ^c   Yang, Xiaojing ^b   Ding, Zongmei ^b   Yao, Li ^b   Huang, Yuejiao ^b   Wang, Chun ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b NANTONG MEDICAL COLLEGE   (China)

^c NANTONG UNIVERSITY   (China)

Author keywords

AGS3; Apoptosis; CAM DR; MM

Indexed keywords

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GUANINE NUCLEOTIDE DISSOCIATION INHIBITORS; HUMANS; MULTIPLE MYELOMA;

EID: 84898467283     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-013-1484-8     Document Type: Article

References (41)

1. Li B, Wang XD, Sun X, Ma J, Yang Y, Ma X. Lack of association between TNF-alpha promoter polymorphisms and multiple myeloma: a meta-analysis. Leuk Res. 2013;37(1):50-7.
2. Lee SW, Cho HY, Na G, Yoo MR, Seo SK, Hur DY, Han J, et al. CD40 stimulation induces vincristine resistance via AKT activation and MRP1 expression in a human multiple myeloma cell line. Immunol Lett. 2012;144(1-2):41-8.
3. Tohnya TM, Figg WD. Immunomodulation of multiple myeloma. Cancer Biol Ther. 2004;3(11):1060-1. (Pubitemid 41350985)
4. Zheng Y, Yang J, Qian J, Qiu P, Hanabuchi S, Lu Y, Wang Z, et al. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia. 2013;27(3):702-10.
5. Hazlehurst LA, Argilagos RF, Emmons M, Boulware D, Beam CA, Sullivan DM, Dalton WS. Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells. Cancer Res. 2006;66(4):2338-45.
6. Balakumaran A, Robey PG, Fedarko N, Landgren O. Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis. Expert Rev Mol Diagn. 2010;10(4):465-80.
7. Yanamandra N, Colaco NM, Parquet NA, Buzzeo RW, Boulware D, Wright G, Perez LE, et al. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res. 2006;12(2):591-9. (Pubitemid 43166154)
8. Landowski TH, Olashaw NE, Agrawal D, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene. 2003;22(16):2417-21. (Pubitemid 36560725)
9. Takesono A, Cismowski MJ, Ribas C, Bernard M, Chung P, Hazard SR, Duzic E, et al. Receptor-independent activators of heterotrimeric G-protein signaling pathways. J Biol Chem. 1999;274(47):33202-5. (Pubitemid 129511615)
10. De Vries L, Fischer T, Tronchere H, Brothers GM, Strockbine B, Siderovski DP, Farquhar MG. Activator of G protein signaling 3 is a guanine dissociation inhibitor for Galpha i subunits. Proc Natl Acad Sci USA. 2000;97(26):14364-9.
11. Bernard ML, Peterson YK, Chung P, Jourdan J, Lanier SM. Selective interaction of AGS3 with G-proteins and the influence of AGS3 on the activation state of G-proteins. J Biol Chem. 2001;276(2):1585-93. (Pubitemid 32096595)
12. Pizzinat N, Takesono A, Lanier SM. Identification of a truncated form of the G-protein regulator AGS3 in heart that lacks the tetratricopeptide repeat domains. J Biol Chem. 2001;276(20):16601-10.
13. Pattingre S, De Vries L, Bauvy C, Chantret I, Cluzeaud F, Ogier-Denis E, Vandewalle A, et al. The G-protein regulator AGS3 controls an early event during macroautophagy in human intestinal HT-29 cells. J Biol Chem. 2003;278(23):20995-1002. (Pubitemid 36806409)
14. Pattingre S, Petiot A, Codogno P. Analyses of Galpha-interacting protein and activator of G-protein-signaling-3 functions in macroautophagy. Methods Enzymol. 2004;390:17-31. (Pubitemid 39370642)
15. Groves B, Gong Q, Xu Z, Huntsman C, Nguyen C, Li D, Ma D. A specific role of AGS3 in the surface expression of plasma membrane proteins. Proc Natl Acad Sci USA. 2007;104(46):18103-8. (Pubitemid 350210827)
16. Blumer JB, Cismowski MJ, Sato M, Lanier SM. AGS proteins: receptor-independent activators of G-protein signaling. Trends Pharmacol Sci. 2005;26(9):470-6. (Pubitemid 41207879)
17. Sanada K, Tsai LH. G protein betagamma subunits and AGS3 control spindle orientation and asymmetric cell fate of cerebral cortical progenitors. Cell. 2005;122(1):119-31. (Pubitemid 40977945)
18. Wang W, Li Q, Zou F, Yu Z, Wang Y, Lu T, Hu T, et al. Increased expression of AGS3 in rat brain cortex after traumatic brain injury. J Neurosci Res. 2013;91(5):726-36.
19. Finkbeiner S. CREB couples neurotrophin signals to survival messages. Neuron. 2000;25(1):11-4. (Pubitemid 30316505)
20. Raghupathi R, Strauss KI, Zhang C, Krajewski S, Reed JC, McIntosh TK. Temporal alterations in cellular Bax:Bcl-2 ratio following traumatic brain injury in the rat. J Neurotrauma. 2003;20(5):421-35. (Pubitemid 36617946)
21. Ola MS, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem. 2011;351(1-2):41-58.
22. Clark RS, Chen J, Watkins SC, Kochanek PM, Chen M, Stetler RA, Loeffert JE, et al. Apoptosis-suppressor gene bcl-2 expression after traumatic brain injury in rats. J Neurosci. 1997;17(23):9172-82. (Pubitemid 27498445)
23. Fuenzalida K, Quintanilla R, Ramos P, Piderit D, Fuentealba RA, Martinez G, Inestrosa NC, et al. Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J Biol Chem. 2007;282(51):37006-15.
24. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93(5):1658-67. (Pubitemid 29102494)
25. Emmons MF, Gebhard AW, Nair RR, Baz R, McLaughlin ML, Cress AE, Hazlehurst LA. Acquisition of resistance toward HYD1 correlates with a reduction in cleaved alpha4 integrin expression and a compromised CAM-DR phenotype. Mol Cancer Ther. 2011;10(12):2257-66.
26. Hazlehurst LA, Dalton WS. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev. 2001;20(1-2):43-50. (Pubitemid 34074677)
27. Anderson KC, Kyle RA, Dalton WS, Landowski T, Shain K, Jove R, Hazlehurst L, et al. Multiple myeloma: new insights and therapeutic approaches. Hematology Am Soc Hematol Educ Program. 2000;2000:147-65.
28. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860-73.
29. Kobune M, Chiba H, Kato J, Kato K, Nakamura K, Kawano Y, Takada K, et al. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism. Mol Cancer Ther. 2007;6(6):1774-84. (Pubitemid 46954054)
30. Yanamandra N, Colaco NM, Parquet NA, Buzzeo RW, Boulware D, Wright G, Perez LE, et al. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin Cancer Res. 2006;12(2):591-9. (Pubitemid 43166154)
31. Gauduchon J, Gouilleux F, Maillard S, Marsaud V, Renoir JM, Sola B. 4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members. Clin Cancer Res. 2005;11(6):2345-54. (Pubitemid 40490196)
32. Lin J, Wu Y, Yang D, Zhao Y. Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo. Oncol Rep. 2013;30(2):731-8.
33. Reed JC, Jurgensmeier JM, Matsuyama S. Bcl-2 family proteins and mitochondria. Biochim Biophys Acta. 1998;1366(1-2):127-37. (Pubitemid 28467027)
34. Wilson BE, Mochon E, Boxer LM. Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol. 1996;16(10):5546-56. (Pubitemid 26315074)
35. Yamamoto KK, Gonzalez GA, Biggs WR, Montminy MR. Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREB. Nature. 1988;334(6182):494-8.
36. Shaywitz AJ, Greenberg ME. CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem. 1999;68:821-61. (Pubitemid 29449210)
37. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol. 2001;2(8):599-609. (Pubitemid 33674011)
38. Peterson YK, Bernard ML, Ma H, Hazard SR, Graber SG, Lanier SM. Stabilization of the GDP-bound conformation of Gialpha by a peptide derived from the G-protein regulatory motif of AGS3. J Biol Chem. 2000;275(43):33193-6.
39. Natochin M, Lester B, Peterson YK, Bernard ML, Lanier SM, Artemyev NO. AGS3 inhibits GDP dissociation from g alpha subunits of the Gi family and rhodopsin-dependent activation of transducin. J Biol Chem. 2000;275(52):40981-5. (Pubitemid 32054923)
40. Blumer JB, Lord K, Saunders TL, Pacchioni A, Black C, Lazartigues E, Varner KJ, et al. Activator of G protein signaling 3 null mice: I. unexpected alterations in metabolic and cardiovascular function. Endocrinology. 2008;149(8):3842-9.
41. Sakamoto KM, Frank DA. CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy. Clin Cancer Res. 2009;15(8):2583-7.